Fig 2: Expression of FAK kinase and alternative transcripts in ovarian cancer cell lines. (A) Expression of FAK was assessed in SKOV3, NIH-OVCAR3 and TOV-112D ovarian cancer-derived cells with western blotting using an anti-FAK kinase domain antibody. HeLa cells were included as a FAK expression control. Detection of GAPDH was used as loading control. (B) Expression of FAK28,6, FAK°, and FAK28 alternative transcripts were investigated in SKOV3, NIH-OVCAR3 and TOV-112D cells with reverse transcription-semi-quantitative polymerase chain reaction. Expression of the β-actin gene was included as an internal control. Amplified fragments from each cell line were analyzed in separate agarose gels. FAK, focal adhesion kinase.

Fig 3: Densitometric analysis of FAK expression in ovarian cancer and healthy ovary samples. Following immunohistochemistry staining, three microphotographs were captured for each serous and mucinous cystadenoma, borderline tumor and ovarian carcinoma samples. Healthy ovary samples were included as negative controls. The samples were analyzed as described in the Materials and methods section. Relative intensity of (A) FAK kinase and (B) FAT domain immunostaining are depicted. Error bars represent the standard deviation of the mean. Differences were calculated using the analysis of variance test, considering a value of P<0.05 as significant difference. *P<0.05, compared with healthy ovary samples; **P<0.05, compared with cystadenoma samples; ***P<0.05, compared with borderline serous tumor samples. FAT, focal adhesion targeting; FAK, focal adhesion kinase.